Fig. 4.

Fig. 4. Effect of HPH on skin lesions and spleen changes in DNCB-sensitized BALB/c mice. (A) BALB/c mice were sensitized to DNCB (1% or 0.5%) three times/week for 4 weeks. HPH (200 or 400 μL) was subcutaneously injected twice/ week, and DEX (positive control group; 10 mg/kg) was intraperitoneally injected three times/week. (B) Images were taken at the end of the experiment. The images display representative dorsal skin lesions in each group. (C) Images of spleens harvested from BALB/c mice are shown. (D) The dermatitis score reflecting erythema, dryness, and scarring in skin lesions of individual mice was assessed. (E) For each mouse, the body weight-adjusted spleen weight was quantified. (F) The body weight of each group. (G) For each mouse, the calf muscle was harvested and the body weight-adjusted muscle mass quantified. Data are expressed as the mean ± S.D. *p < 0.05, **p < 0.01, ****p < 0.0001 compared with the control group. ^#p < 0.05, ^####p < 0.0001 compared with the normal group. N, normal group; C, DNCB-induced control group; HPH200, HPH 200 μL-administered group; HPH400, HPH 400 μL-administrated group; DEX, dexamethasone (10 mg/kg)-administered group.

© J. Microbiol. Biotechnol.